Igenica Biotherapeutics Turns to Waters Technologies to Accelerate Antibody Drug Conjugate (ADC) Development

Library Number:
LITR134819483
Part Number:
720005149en
Author(s):
Waters Corporation and Igenica Biotherapeutics
Content Type:
Literature
Content Subtype:
Case Studies

Igenica Biotherapeutics, a Burlingame, Calif., U.S. biotechnology company with a promising anti-cancer antibody in a Phase 1 clinical trial, has innovative technology platforms to discover and develop antibody drug conjugates (ADCs) for cancer treatment.

To fulfill the company’s goal of quickly moving an ADC-based therapeutics out of preclinical development and into the clinic, Igenica wanted new dedicated, industry-standard instrumentation to fully analyze the complexity and variation within an ADC’s three parts: the antibody, the toxic drug, and the linker that binds them together.

As a result, Igenica deployed Waters Biopharmaceutical Platform Solution with UNIFI, which includes the ACQUITY UPLC H-Class System, Xevo G2-S QTof Mass Spectrometer, and UNIFI Scientific Information System.

“The Waters Biopharmaceutical Platform has provided a superior window of insight into the molecules we are making,” said Mark R. Flory, Ph.D., a principal scientist at Igenica. “It will help in our efforts to accelerate clinical trials with ADCs.”


Title Format File Size
720005149en PDF 744.38kB